ERBB2 and non-small cell lung carcinoma: In the umbrella (HUDSON) (NCT03334617) trial, patients with NSCLC with HER2 overexpression (n = 23) or ERBB2 mutations (n = 20) who were previously treated with ICIs were administered a combination of T-DXd and durvalumab [95].